BrainsWay 2021 logo.jpg
BrainsWay Announces Significant Expansion on U.S. East Coast
16 sept. 2024 07h30 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay 2021 logo.jpg
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals
10 sept. 2024 08h00 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...
BrainsWay 2021 logo.jpg
BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer
29 août 2024 07h30 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay 2021 logo.jpg
BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights
06 août 2024 07h30 HE | BrainsWay
Generated Robust 28% Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for...
BrainsWay 2021 logo.jpg
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
23 juil. 2024 08h00 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay 2021 logo.jpg
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
17 juin 2024 07h30 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay 2021 logo.jpg
BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression
10 juin 2024 07h30 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay 2021 logo.jpg
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
03 juin 2024 07h30 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay 2021 logo.jpg
BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights
08 mai 2024 07h30 HE | BrainsWay
Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations...
BrainsWay 2021 logo.jpg
BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024
24 avr. 2024 08h00 HE | BrainsWay
BURLINGTON, Mass. and JERUSALEM, April 24, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...